Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24...